Eurogentec | GenomeWeb

Eurogentec

As part of the deal, MoBiTec will offer Eurogentec's qPCR kits, oligonucleotides, and other products.

Patent watchdog firm Troll Busters has chosen to abandon its lawsuit against more than a dozen life science companies for false patent marking related to various nucleic acid detection, amplification, and cloning technologies, according to recently filed court documents.

A US district court has dismissed a lawsuit filed earlier this year against more than a dozen life science companies alleging that they falsely marked certain nucleic acid detection, amplification, and cloning technologies as being patented after the relevant patents expired.

Product Watch

Premium

Life Technologies' Custom Plus TaqMan assays, mouse copy number assays, Qubit 2.0 fluorometer, and bovine diarrhea diagnostic kit; TATAA Biocenter's new services; Amresco's Ready PCR Mix, 2X; and Eurogentec AnaSpec's FAST master mixes.

Product Watch

Premium

AnaSpec introduces Eurogentec's Mesa Blue qPCR MasterMix; Idaho Technology launches training kit for Razor line of biothreat detection systems.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The tech-transfer and license agreement pertains to Eurogentec's processes for manufacturing diagnostic oligonucleotides and PCR enzymes, a company official said.

BD expects to use Eurogentec's technology to develop molecular diagnostic kits.

The company's Nippon EGT arm has been certified for its IVD oligonucleotide production business.

The purchase, for an undisclosed amount, gives Eurogentec AnaSpec's catalog antibodies and peptides and dye technology, while increasing the Belgian company's visibility in the US.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.